Interventions for lowering plasma homocysteine levels in kidney transplant recipients

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 5, 2015, Pages

  Kang, Amy ^a   Nigwekar, Sagar U ^b   Perkovic, Vlado ^c   Kulshrestha, Satyarth ^d   Zoungas, Sophia ^e   Navaneethan, Sankar D ^f   Cass, Alan ^g   Gallagher, Martin P ^c   Ninomiya, Toshiharu ^c   Strippoli, Giovanni F M ^h,i,j,k   Jardine, Meg J ^l,m  

^a UNIVERSITY OF SYDNEY   (Australia)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^d UNIVERSITY OF IOWA   (United States)

^e MONASH UNIVERSITY   (Australia)

^f LERNER RESEARCH INSTITUTE   (United States)

^g MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^h CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

ⁱ UNIVERSITY OF BARI   (Italy)

^j Diaverum Medical Scientific Office   (Sweden)

^k Diaverum Academy   (Italy)

^l UNIVERSITY OF SYDNEY   (Australia)

^m ANZAC Research Institute   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; HOMOCYSTEINE; VITAMIN B GROUP; VITAMIN B COMPLEX;

ALL CAUSE MORTALITY; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; HEART INFARCTION; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT OUTCOME; BLOOD; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; MORTALITY;

CARDIOVASCULAR DISEASES; CAUSE OF DEATH; FOLIC ACID; HOMOCYSTEINE; HUMANS; KIDNEY TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VITAMIN B COMPLEX;

EID: 84945431945     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007910.pub2     Document Type: Review

References (83)

1. Bostom AG, Carpenter M, Kusek J. Baseline characteristics of the folic acid for vascular outcome reduction in transplantation (FAVOURIT) trial [abstract no: PUB316]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):883A. [CENTRAL: CN-00724882]
2. Bostom AG, Carpenter MA, Hunsicker L, Jacques PF, Kusek JW, Levey AS. Baseline characteristics of participants in the folic acid for vascular outcome reduction in transplantation (FAVORIT) trial [abstract no: 827]. American Journal of Transplantation 2009;9(Suppl 2):429.
3. Bostom AG, Carpenter MA, Hunsicker L, Jacques PF, Kusek JW, Levey AS, et al. Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. American Journal of Kidney Diseases 2009;53(1):121-8. [MEDLINE: 19022547]
4. Bostom AG, Carpenter MA, Kusek JW, Hunsicker LG, Jacques P, Levey AS, et al. Homocysteine-lowering in chronic stable renal transplant recipients: the FAVORIT Trial [abstract no: LB001]. American Society of Nephrology Renal Week; 2009 Oct 27-Nov 1; San Diego, CA. 2009.
5. Bostom AG, Carpenter MA, Kusek JW, Hunsicker LG, Pfeffer MA, Levey AS, et al. Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial. American Heart Journal 2006;152(3):448.e1-7. [MEDLINE: 16923411]
6. Bostom AG, Carpenter MA, Kusek JW, Levey AS, Hunsicker L, Pfeffer MA, et al. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. Circulation 2011;123(16):1763-70. [MEDLINE: 21482964]
7. Carpenter M, Bostom A, Hunsicker L, Ivanova A, Kasiske B, Kusek J, et al. Higher systolic blood pressure is associated with increased cardiovascular risk in patients with hypertension in the Folic Acid for Vascular Outcome Reduction in Transplantation trial [abstract]. American Journal of Transplantation 2011;11(Suppl 2):375. [EMBASE: 70406228]
8. Carpenter MA, Bostom A, Kusek J, Adey D, Cole E, House A, et al. Untreated CVD risk factors in chronic, stable kidney transplant recipients at baseline in the folic acid for vascular outcome reduction (FAVORIT) study [abstract no: PUB271]. Journal of the American Society of Nephrology 2009;20:888A. [CENTRAL: CN-00740518]
9. Carpenter MA, John A, Weir MR, Smith SR, Hunsicker L, Kasiske BL, et al. BP, cardiovascular disease, and death in the Folic Acid for Vascular Outcome Reduction in Transplantation Trial. Journal of the American Society of Nephrology 2014;25(7):1554-62. [MEDLINE: 24627349]
10. Carpenter MA, Weir MR, Adey DB, House AA, Bostom AG, Kusek JW. Inadequacy of cardiovascular risk factor management in chronic kidney transplantation - evidence from the FAVORIT study. Clinical Transplantation 2012;26(4):E438-46. [MEDLINE: 22775763]
11. Troen AM, Scott TM, D'Anci KE, Moorthy D, Dobson B, Rogers G, et al. Cognitive dysfunction and depression in adult kidney transplant recipients: baseline findings from the FAVORIT Ancillary Cognitive Trial (FACT). Journal of Renal Nutrition 2012;22(2):268-76.e1-3. [MEDLINE: 22153382]
12. Weiner DE, Carpenter MA, Levey AS, Ivanova A, Cole EH, Hunsicker L, et al. Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial. American Journal of Transplantation 2012;12(9):2437-45. [MEDLINE: 22594581]
13. Weir MR, Gravens-Muller L, Costa N, Ivanova A, Manitpisitkul W, Bostom AG, et al. Safety events in kidney transplant recipients: Results from the Folic Acid for Vascular Outcome Reduction in Transplant Trial. Transplantation 2014:e-pub ahead of print. [PUBMED: 25393158]
14. Ardalan MR, Mortazavi M, Etemadi J. Hyperhomocysteinemia and its therapy in renal transplant recipients with combination of vit B6, vit B12 and folic acid [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):509-10. [CENTRAL: CN-00444217]
15. Austen SK, Fassett RG, Geraghty DP, Coombes JS. Folate supplementation fails to affect vascular function and carotid artery intima media thickness in cyclosporin A-treated renal transplant recipients. Clinical Nephrology 2006; Vol. 66, issue 5:373-9. [MEDLINE: 17140167]
16. Beaulieu AJ, Gohh RY, Han H, Hakas D, Jacques PF, Selhub J, et al. Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients. Arteriosclerosis, Thrombosis & Vascular Biology 1999; Vol. 19, issue 12:2918-21. [MEDLINE: 10591669]
17. Gohh RY, Beaulieu AJ, Han H, Hakas D, Jacques PF, Selhub J, et al. Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients (RTR) [abstract]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):730A. [CENTRAL: CN-00626082]
18. Biagini M, Bertoni E, Marcucci R, Zanazzi M, Rosati A, Fedi S, et al. Vitamin supplementation reduces the progression atherosclerosis in hyperhomocysteinemic renal transplant recipients [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami, FL. 2002. [CENTRAL: CN-00415280]
19. Bostom AG, Gohh RY, Beaulieu A, Nadeau MR, Hume AL, Jacques PF, et al. Homocysteine-lowering treatment of renal transplant recipients [abstract]. Journal of the American Society of Nephrology 1997;8(Program & Abstracts):675A. [CENTRAL: CN-00444499]
20. Bostom AG, Gohh RY, Beaulieu AJ, Nadeau MR, Hume AL, Jacques PF, et al. Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial. Annals of Internal Medicine 1997; Vol. 127, issue 12:1089-92. [MEDLINE: 9412311]
21. Bostom AG, Shemin D, Bagley P, Massy ZA, Zanabli A, Christopher K, et al. Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. [erratum appears in Circulation 2000 Aug 1;102(5):598]. Circulation 2000;101(24):2829-32. [MEDLINE: 10859289]
22. Bostom AG, Shemin D, Bagley P, Massy ZA, Zanabli A, Spiegel P, et al. Reduced folates are an expensive treatment for hyperhomocysteinemia in hemodialysis patients with no greater efficacy than folic acid: results of a controlled comparison study [abstract]. Journal of the American Society of Nephrology 2000;11(Sept):257A. [CENTRAL: CN-00550713]
23. Bostom AG, Shemin D, Gohh RY, Beaulieu AJ, Bagley P, Massy ZA, et al. Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients. Kidney International - Supplement 2001;59(78):S246-52. [MEDLINE: 11169020]
24. Bostom AG, Shemin D, Gohh RY, Beaulieu AJ, Jacques PF, Dworkin L, et al. Treatment of mild hyperhomocysteinemia in renal transplant recipients versus hemodialysis patients. Transplantation 2000;69(10):2128-31. [MEDLINE: 10852611]
25. Jurewicz WA. Tacrolimus versus cyclosporin immunosuppression: long-term outcome in renal transplantation. Nephrology Dialysis Transplantation 2003 May;18 Suppl 1:i7-11. [MEDLINE: 12738757]
26. Juskowa J, Lewandowska M, Bartlomiejczyk I, Foroncewicz B, Korabiewska I, Niewczas M, et al. Physical rehabilitation and risk of atherosclerosis after successful kidney transplantation. Transplantation Proceedings 2006;38(1):157-60. [MEDLINE: 16504691]
27. Kaisar M, Armstrong K, Prins J, Marwick T, Johnson D, Hawley C, et al. The impact of aggressive cardiovascular risk modification on carotid intima media thickness and brachial artery reactivity in renal transplant recipients [abstract no: 132]. Nephrology 2008;13(Suppl 3):A134. [CENTRAL: CN-00766731]
28. Kaisar MO, Armstrong K, Hawley C, Campbell S, Mudge D, Johnson DW, et al. Adiponectin is associated with cardiovascular disease in male renal transplant recipients: baseline results from the LANDMARK 2 study. BMC Nephrology 2009;10:29. [MEDLINE: 19821969]
29. Lash JP, Cardoso LR, Mesler PM, Walczak DA, Pollak R. The effect of garlic on hypercholesterolemia in renal transplant patients. Transplantation Proceedings 1998;30(1):189-91. [MEDLINE: 9474997]
30. Manrique J, Diaz A, Gavira JJ, Hernandez A, Pujante D, Errasti P. Preliminary results of the effect of treatment of hyperhomocysteinemia and its relationship with inflammation, coagulation status, and endothelial function after renal transplantation. Transplantation Proceedings 2005;37(9):3782-4. [MEDLINE: 16386537]
31. Manrique J, Errasti P, Orbe J, Paramo JA, Rodriguez JA. Folic acid and B vitamins improve hyperhomocysteinemia-induced cardiovascular risk profile in renal transplant recipients. Journal of Thrombosis & Haemostasis 2007;5(5):1072-6. [MEDLINE: 17461937]
32. Bertoni E, Rosati A, Zanazzi M, Marcucci R, Fedi S, Abbate R, et al. Vitamin supplement reduces the progression of atherosclerosis in hyperhomocysteinemic renal transplant recipients [abstract no: F-FC055]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):74P. [CENTRAL: CN-00444418]
33. Marcucci R, Bertoni E, Zanazzi M, Rosati A, Fedi S, Rogolino A, et al. Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal transplant recipients [abstract]. Nephrology Dialysis Transplantation 2002;17(Suppl 11):31. [CENTRAL: CN-00520363]
34. Marcucci R, Zanazzi M, Bertoni E, Rosati A, Fedi S, Lenti M, et al. Homocysteine-lowering therapy and carotid intima-media thickness in renal transplant recipients. Transplantation Proceedings 2005;37(6):2491-2. [MEDLINE: 16182720]
35. Marcucci R, Zanazzi M, Bertoni E, Rosati A, Fedi S, Lenti M, et al. Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients. Transplantation 2003;75(9):1551-5. [MEDLINE: 12792513]
36. Rosati A, Bertoni E, Zanazzi M, Marcucci R, Fedi S, Castellani S, et al. Vitamin supplement reduces the progression of atherosclerosis in hyperhomocysteinemic renal transplant recipients [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):510. [CENTRAL: CN-00447462]
37. Nafar M, Khatami F, Kardavani B, Farjad R, Pour-Reza-Gholi F, Firouzan A, et al. Role of folic acid in atherosclerosis after kidney transplant: a double-blind, randomized, placebo-controlled clinical trial. Experimental & Clinical Transplantation 2009;7(1):33-9. [MEDLINE: 19364310]
38. Perez L, Sanchez E, Hernandez D, De La Vega MJ, Alvarez A, Delgado P, et al. Vitamin supplements improve the lipid profile in renal transplant patients: a randomized clinical trial [abstract no: SU-PO994]. Journal of the American Society of Nephrology 2004;15(Oct):747A. [CENTRAL: CN-00677746]
39. Rymarz A, Durlik M, Rydzewski A. Intravenous administration of N-acetylcysteine reduces plasma total homocysteine levels in renal transplant recipients. Annals of Transplantation 2009;14(4):5-9. [MEDLINE: 20009148]
40. Savaj S, Rezakhani S, Porooshani F, Ghods AJ. Effect of folic acid therapy on serum homocysteine level in renal transplant recipients. Transplantation Proceedings 2002;34(6):2419. [MEDLINE: 12270462]
41. Shemin D, Bostom AG, Selhub J. Treatment of hyperhomocysteinemia in end-stage renal disease. American Journal of Kidney Diseases 2001;38(4 Suppl 1):S91-4. [MEDLINE: 11576930]
42. Teplan V, Schuck O, Hyanek J, Poledne R, Vitko S. Effective treatment of hyperhomocysteinemia and obesity reduces the risk after renal transplantation [abstract no: T711]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):509. [CENTRAL: CN-00447972]
43. Xu T, Wang XF, Qu XK, Ye HY, Huang XB, Zhang XP, et al. Treatment of hyperhomocysteinemia and endothelial dysfunction in renal-transplant recipients with vitamin B. Chung-Hua Wai Ko Tsa Chih [Chinese Journal of Surgery] 2005; Vol. 43, issue 14:940-3. [MEDLINE: 16083628]
44. Xu T, Zhang XW, Qu XK, Ye HY, Huang XB, Zhang XP, et al. Treatment of hyperhomocysteinemia and endothelial dysfunction in renal transplant recipients with B vitamins in the Chinese population. Journal of Urology 2008;179(3):1190-4. [MEDLINE: 18206175]
45. Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 2008;299(17):2027-36. [MEDLINE: 18460663]
46. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361(9374):2024-31. [MEDLINE: 12814712]
47. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. New England Journal of Medicine 2006;354(15):1578-88. [MEDLINE: 16531614]
48. CARI Care for kidney transplant recipients. 2012. www.cari.org.au/Transplantation/transplantation%20care%20of%20recipients/transplant_care_of_recipients.html (accessed 23 March 2015).
49. Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Archives of Internal Medicine 2010;170(18):1622-31. [MEDLINE: 20937919]
50. Crider KS, Bailey LB, Berry RJ. Folic acid food fortification-its history, effect, concerns, and future directions. Nutrients 2011;3(3):370-84. [MEDLINE: 22254102]
51. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997;90(1):1-11. [MEDLINE: 9207431]
52. Ducloux D, Motte G, Challier B, Gibey R, Chalopin JM. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. Journal of the American Society of Nephrology 2000;11(1):134-7. [MEDLINE: 10616849]
53. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.5. Cardiovascular risks. Hyperhomocysteinaemia. Nephrology Dialysis Transplantation 2002;17 Suppl 4:28-9. [MEDLINE: 12091633]
54. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34. [MEDLINE: 9310563]
55. Gallagher M, Jardine M, Perkovic V, Cass A, McDonald S, Petrie J, et al. Cyclosporine withdrawal improves long-term graft survival in renal transplantation. Transplantation 2009;87(12):1877-83. [MEDLINE: 19543068]
56. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120]
57. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
58. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288(16):2015-22. [MEDLINE: 12387654]
59. Hubner RA, Houlston RD, Muir KR. Should folic acid fortification be mandatory? No. BMJ 2007;334(7606):1253. [MEDLINE: 17569932]
60. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007;298(10):1163-70. [MEDLINE: 17848650]
61. Jardine MJ, Kang A, Zoungas S, Navaneethan SD, Ninomiya T, Nigwekar SU, et al. The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis. BMJ 2012;344:e3533. [MEDLINE: 22695899]
62. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ. Cardiovascular disease after renal transplantation. Journal of the American Society of Nephrology 1996;7(1):158-65. [MEDLINE: 8808124]
63. Kidney Disease: Improving Global Outcomes (KDIGO)Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. American Journal of Transplantation 2009;9 Suppl 3:S1-157. [MEDLINE: 19845597]
64. Lang D, Kredan MB, Moat SJ, Hussain SA, Powell CA, Bellamy MF, et al. Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta: role for superoxide anions. Arteriosclerosis, Thrombosis, & Vascular Biology 2000;20(2):422-7. [MEDLINE: 10669639]
65. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. Journal of Clinical Investigation 1991;88(6):1906-14. [MEDLINE: 1661291]
66. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. Journal of Clinical Investigation 1996;98(1):24-9. [MEDLINE: 8690798]
67. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. New England Journal of Medicine 2006;354(15):1567-77. [MEDLINE: 16531613]
68. Massy ZA, Chadefaux-Vekemans B, Chevalier A, Bader CA, Drüeke TB, Legendre C, et al. Hyperhomocysteinaemia: a significant risk factor for cardiovascular disease in renal transplant recipients. Nephrology Dialysis Transplantation 1994;9(8):1103-8. [MEDLINE: 7800208]
69. McCully KS. Homocysteine and vascular disease. Nature Medicine 1996;2(4):386-9. [MEDLINE: 8597939]
70. National Institutes of Health. U.S. Renal Data System, USRDS 2007 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. 2007. www.usrds.org/atlas07.aspx (accessed 23 March 2015).
71. Orioli IM, Lima do Nascimento R, Lopez-Camelo JS, Castilla EE. Effects of folic acid fortification on spina bifida prevalence In Brazil. Birth Defects Research 2011;91(9):831-5. [MEDLINE: 21630426]
72. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA 2002;288(8):973-9. [MEDLINE: 12190367]
73. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. Journal of Clinical Investigation 1986;77(4):1370-6. [MEDLINE: 3514679]
74. Holt S, Goldsmith D. Cardiovascular disease in CKD. 2010. www.renal.org/guidelines/modules/cardiovascular-disease-in-ckd#Summary2 (accessed 23 March 2015).
75. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291(5):565-75. [MEDLINE: 14762035]
76. Vianna AC, Mocelin AJ, Matsuo T, Morais-Filho D, Largura A, Delfino VA, et al. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events. Hemodialysis International 2007;11(2):210-6. [MEDLINE: 17403173]
77. Vollset SE, Clarke R, Lewington S, Ebbing M, Halsey J, Lonn E, et al. Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50, 000 individuals. Lancet 2013;381(9871):1029-36. [MEDLINE: 23352552]
78. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325(7374):1202. [MEDLINE: 12446535]
79. Winkelmayer WC, Kramar R, Curhan GC, Chandraker A, Endler G, Födinger M, et al. Fasting plasma total homocysteine levels and mortality and allograft loss in kidney transplant recipients: a prospective study. Journal of the American Society of Nephrology 2005;16(1):255-60. [MEDLINE: 15563562]
80. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. Journal of the American Society of Nephrology 2004;15(2):420-6. [MEDLINE: 14747389]
81. Yap S. Classical homocystinuria: vascular risk and its prevention. Journal of Inherited Metabolic Disease 2003;26(2-3):259-65. [MEDLINE: 12889665]
82. Zoungas S, McGrath BP, Branley P, Kerr PG, Muske C, Wolfe R, et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. Journal of the American College of Cardiology 2006;47(6):1108-16. [MEDLINE: 16545638]
83. Kang A, Nigwekar SU, Perkovic V, Kulshrestha S, Zoungas S, Navaneethan SD, et al. Interventions for lowering plasma homocysteine levels in kidney transplant recipients. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007910]